FAQ

CSL112

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
0120132017

Related topics

Related topics

1 relation

Broader (1)

High Density Lipoproteins

Related mentions per year

Related mentions per year

1952-2018
1960198020002020
CSL112
High Density Lipoproteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
OBJECTIVE CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early… (More)
Is this relevant?
2017
2017
Dyslipidaemia: Apo-AI infusion after acute MI
 
Is this relevant?
2016
2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction
BACKGROUND Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated… (More)
Is this relevant?
2016
2016
Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.
RATIONALE CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table II
Is this relevant?
2016
2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a…
BACKGROUND Despite aggressive pharmacotherapy and stenting, there is a residual risk of major adverse cardiovascular events among… (More)
Is this relevant?
2015
2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
BACKGROUND CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events… (More)
Is this relevant?
2014
2014
A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
CSL112 is apoA-I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high-density lipoprotein (HDL… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
OBJECTIVE The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?